2-H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-
RTECS #
DF2100000
CAS #
Updated
March 2019
Molecular Weight
315.73
Molecular Formula
C15H10ClN3O3
Synonyms
1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
Antelepsin
Antilepsin
Clonazepam
Clonopin
Iktorivil
Klonopin
Landsen
Rivotril
Ro 5-4023
5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
Antelepsin
Antilepsin
Clonazepam
Clonopin
Iktorivil
Klonopin
Landsen
Rivotril
Ro 5-4023
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/mouse | 3300 µg/kg (6-16D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system | TXAPA9 40,365,1977 |
| oral/rabbit | 24 mg/kg (6-13D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | YACHDS 5,2457,1977 |
| subcutaneous/rat | 1750 µg/kg (14-20D pregnant) | Reproductive: Effects on newborn: Biochemical and metabolic | LIFSAK 44,493,1989 |
| subcutaneous/mouse | 8 mg/kg (9D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Central nervous system | DGDFA5 22,61,1980 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 0.1 gm/L | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,1274,2014 |
| In Vitro/Human, liver | Inhibitor Concentration (50 percent kill): >200 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 30,429,2015 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): >100 µmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 30,429,2015 |
| intraperitoneal/mouse | lowest published toxic dose: 0.5 mg/kg | Behavioral: Antianxiety | NETEEC 61,123,2017 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 13300 mg/kg | IYKEDH 11,811,1980 | |
| intraperitoneal/mouse | lowest published toxic dose: 0.02 mg/kg | Behavioral: Anticonvulsant | EURNE* 14,77,2003 |
| intraperitoneal/mouse | lowest published toxic dose: 11.3 mg/kg | Behavioral: Change in psychophysiological tests | EURNE* 14,77,2003 |
| intraperitoneal/mouse | lowest published toxic dose: 0.11 mg/kg | Brain and Coverings: Other degenerative changes | JPETAB 316,1378,2006 |
| intraperitoneal/mouse | lowest published toxic dose: 0.8 mg/kg | Behavioral: Convulsions or effect on seizure threshold | JPETAB 316,1378,2006 |
| intraperitoneal/mouse | lowest published toxic dose: 0.028 mg/kg | Behavioral: Anticonvulsant Behavioral: Ataxia | PHREP* 57,458,2005 |
| intraperitoneal/rat | lethal dose (50 percent kill): 14200 mg/kg | IYKEDH 11,811,1980 | |
| intraperitoneal/rat | lowest published toxic dose: 1 mg/kg | Brain and Coverings: Recordings from specific areas of CNS | EJPHAZ 466,255,2003 |
| intraperitoneal/rat | lowest published toxic dose: 0.005 mg/kg | Behavioral: Anticonvulsant | EURNE* 12,225,2002 |
| intraperitoneal/rat | lowest published toxic dose: 0.25 mg/kg | Endocrine: Hyperglycemia | BJMRDK 34,57,2001 |
| intravenous/man | lowest published toxic dose: 0.0143 mg/kg | Behavioral: Somnolence (general depressed activity) Endocrine: Hyperglycemia | BMCCP* 4,3,2004 |
| intravenous/mouse | lethal dose (50 percent kill): >18 mg/kg | IYKEDH 11,811,1980 | |
| oral/man | lowest published toxic dose: 21 mg/kg/26W- intermittent | Peripheral Nerve and Sensation: Fasciculations | PGMJAO 63,311,1987 |
| oral/man | lowest published toxic dose: 1329 µg/kg/31D- intermittent | Liver: Liver function tests impaired | AJGAAR 83,576,1988 |
| oral/monkey | lowest published toxic dose: 0.05 mg/kg | Behavioral: Antianxiety | JPETAB 303,777,2002 |
| oral/mouse | lowest published toxic dose: 0.1 mg/kg | Behavioral: Anticonvulsant | JOETD7 76,145,2001 |
| oral/mouse | lowest published toxic dose: 0.1 mg/kg | JOETD7 76,145,2001 | |
| oral/mouse | lethal dose (50 percent kill): 2 gm/kg | PJPPAA 35,77,1983 | |
| oral/rat | lowest published toxic dose: 0.2 mg/kg | Endocrine: Change in GH | PHTOEH 71,75,1992 |
| oral/rat | lowest published toxic dose: 1 mg/kg | Endocrine: Change in LH | PHTOEH 71,75,1992 |
| oral/rat | lethal dose (50 percent kill): >15 gm/kg | NIIRDN 6,235,1982 | |
| subcutaneous/mouse | lethal dose (50 percent kill): >10 gm/kg | NIIRDN 6,235,1982 | |
| subcutaneous/rat | lethal dose (50 percent kill): >10 gm/kg | NIIRDN 6,235,1982 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/human | lowest published toxic dose: 15.6 mg/kg/78W- intermittent | Behavioral: Antipsychotic Behavioral: Change in psychophysiological tests | EURNE* 13,129,2003 |
| oral/human | lowest published toxic dose: 0.3 mg/kg/3W- intermittent | Behavioral: Somnolence (general depressed activity) Behavioral: Muscle weakness Gastrointestinal: Nausea or vomiting | APHRER 38,1395,2004 |
| oral/rat | lowest published toxic dose: 7280 mg/kg/26W- intermittent | Brain and Coverings: Changes in brain weight Kidney, Ureter, and Bladder: Changes in bladder weight Endocrine: Changes in thyroid weight | YACHDS 4,1441,1976 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| TOXICOLOGY REVIEW | MUREAV 488,151,2001 | |
| TOXICOLOGY REVIEW | TPHSDY 24,542,2003 | |
| TOXICOLOGY REVIEW | AJEMEN 22,404,2004 | |
| TOXICOLOGY REVIEW | DERCL* 25,233,2007 | |
| TOXICOLOGY REVIEW | NCLNA* 16,503,1998 | |
| TOXICOLOGY REVIEW | FCLPH* 21(Suppl 1),53,2007 | |
| TOXICOLOGY REVIEW | FCLPH* 21(Suppl 1),80,2007 | |
| TOXICOLOGY REVIEW | FCLPH* 22(Suppl 1),29,2008 | |
| TOXICOLOGY REVIEW | FCLPH* 22(Suppl 1),95,2008 | |
| TOXICOLOGY REVIEW | FCLPH* 22(Suppl 1),96,2008 | |
| TOXICOLOGY REVIEW | NBREV* 9,133,1985 | |
| TOXICOLOGY REVIEW | FCLPH* 23(Suppl 1),32,2009 | |
| TOXICOLOGY REVIEW | FCLPH* 23(Suppl 1),51,2009 | |
| TOXICOLOGY REVIEW | FCLPH* 23(Suppl 1),91,2009 | |
| TOXICOLOGY REVIEW | FCLPH* 23(Suppl 1),96,2009 | |
| TOXICOLOGY REVIEW | MUREAV 750,1,2012 | |
| TOXICOLOGY REVIEW | NETEEC 60,2,2017 |
NIOSH Documentation and Surveillance
Status in Federal Agencies
| Organization | Reference |
|---|---|
| EPA GENETOX PROGRAM 1988, Negative: Body fluid assay; Host-mediated assay |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health